Dose response of pancreatic neuroendocrine tumours treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE

被引：0
|
作者：
Ilan, E. [1 ,2 ,3 ]
Sandstrom, M. [1 ,2 ,3 ]
Garske-Roman, U. [2 ,3 ]
Sundin, A. [2 ,3 ]
Wassberg, C. [2 ,3 ]
Lubberink, M. [1 ,2 ,3 ]
机构：
[1] Sect Med Phys, Uppsala, Sweden
[2] Nucl Med Sect, Uppsala, Sweden
[3] PET, Uppsala, Sweden
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP287
引用
收藏
页码：S223 / S224
页数：2
相关论文
共 50 条
  • [1] Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
    Ilan, Ezgi
    Sandstrom, Mattias
    Wassberg, Cecilia
    Sundin, Anders
    Garske-Roman, Ulrike
    Eriksson, Barbro
    Granberg, Dan
    Lubberink, Mark
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) : 177 - 182
  • [2] Receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumours
    Bodei, L.
    Cremonesi, M.
    Grana, C.
    Bartolomei, M.
    Baio, S.
    Bufi, G.
    Fiorenza, M.
    Obenaus, E.
    Paganelli, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S214 - S214
  • [3] 177Lu-Dotatate Peptide Receptor Radionuclide Therapy Dose Response in Small Intestinal Neuroendocrine Tumors
    Jahn, U. M. M.
    Ilan, E.
    Sandstrom, M.
    Bamerny, M.
    Garske-Roman, U.
    Lubberink, M.
    Sundin, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S157 - S158
  • [4] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors
    Jahn, Ulrika
    Ilan, Ezgi
    Sandstrom, Mattias
    Garske-Roman, Ulrike
    Lubberink, Mark
    Sundin, Anders
    [J]. NEUROENDOCRINOLOGY, 2020, 110 (7-8) : 662 - 670
  • [5] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    D. Levart
    E. Kalogianni
    B. Corcoran
    N. Mulholland
    G. Vivian
    [J]. EJNMMI Physics, 6
  • [6] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    Levart, D.
    Kalogianni, E.
    Corcoran, B.
    Mulholland, N.
    Vivian, G.
    [J]. EJNMMI PHYSICS, 2019, 6 (1)
  • [7] Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with 177Lu-DOTATATE
    Rahul V. Parghane
    Sandip Basu
    [J]. Journal of Nuclear Cardiology, 2020, 27 : 340 - 341
  • [8] Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with 177Lu-DOTATATE
    Parghane, Rahul V.
    Basu, Sandip
    [J]. JOURNAL OF NUCLEAR CARDIOLOGY, 2020, 27 (01) : 340 - 341
  • [9] Towards dose-response relationship in gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs) treated with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT)
    Marin, G.
    Levillain, H.
    Karfis, I.
    Marin, C.
    Vanderlinden, B.
    Reynaert, N.
    Vandenberghe, S.
    Flamen, P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S591 - S592
  • [10] Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
    Hidayati, N. R.
    Poon, A.
    Willowson, K.
    Eslick, E.
    Ryu, H.
    Bailey, D. L.
    [J]. ATOM INDONESIA, 2019, 45 (03) : 147 - 152
12345